J
John H. Healey
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 449
Citations - 31577
John H. Healey is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Sarcoma & Medicine. The author has an hindex of 89, co-authored 415 publications receiving 26848 citations. Previous affiliations of John H. Healey include Beaumont Hospital & Yeshiva University.
Papers
More filters
Journal ArticleDOI
Tumour exosome integrins determine organotropic metastasis
Ayuko Hoshino,Bruno Costa-Silva,Tang-Long Shen,Gonçalo Rodrigues,Ayako Hashimoto,Milica Tesic Mark,Henrik Molina,Shinji Kohsaka,Angela Di Giannatale,Sophia Ceder,Swarnima Singh,Caitlin Williams,Nadine Soplop,Kunihiro Uryu,Lindsay A. Pharmer,Tari A. King,Linda Bojmar,Alexander E. Davies,Yonathan Ararso,Tuo Zhang,Haiying Zhang,Jonathan M. Hernandez,Joshua Mitchell Weiss,Vanessa D. Dumont-Cole,Kimberly Kramer,Leonard H. Wexler,Aru Narendran,Gary K. Schwartz,John H. Healey,Per Sandström,Knut Jørgen Labori,Elin H. Kure,Paul M. Grandgenett,Michael A. Hollingsworth,Maria de Sousa,Sukwinder Kaur,Maneesh Jain,Kavita Mallya,Surinder K. Batra,William R. Jarnagin,Mary S. Brady,Øystein Fodstad,Volkmar Müller,Klaus Pantel,Andy J. Minn,Mina J. Bissell,Benjamin A. Garcia,Yibin Kang,Yibin Kang,Vinagolu K. Rajasekhar,Cyrus M. Ghajar,Irina Matei,Héctor Peinado,Jacqueline Bromberg,Jacqueline Bromberg,David Lyden +55 more
TL;DR: It is demonstrated that exosomes from mouse and human lung-, liver- and brain-tropic tumour cells fuse preferentially with resident cells at their predicted destination, namely lung fibroblasts and epithelial cells, liver Kupffer cells and brain endothelial cells.
Journal ArticleDOI
Chromosomal instability drives metastasis through a cytosolic DNA response.
Samuel F. Bakhoum,Samuel F. Bakhoum,Bryan Ngo,Ashley M. Laughney,Julie Ann Cavallo,Julie Ann Cavallo,Charles J. Murphy,Peter Ly,Pragya Shah,Roshan K. Sriram,Thomas B.K. Watkins,Neil K. Taunk,Mercedes Duran,Mercedes Duran,Chantal Pauli,Christine Shaw,Kalyani Chadalavada,Vinagolu K. Rajasekhar,Giulio Genovese,Subramanian Venkatesan,Nicolai Juul Birkbak,Nicholas McGranahan,Mark R. Lundquist,Quincey LaPlant,John H. Healey,Olivier Elemento,Christine H. Chung,Nancy Y. Lee,Marcin Imielenski,Gouri Nanjangud,Dana Pe'er,Don W. Cleveland,Simon N. Powell,Jan Lammerding,Charles Swanton,Lewis C. Cantley +35 more
TL;DR: It is shown that chromosomally unstable tumour cells co-opt chronic activation of innate immune pathways to spread to distant organs by sustaining a tumour cell-autonomous response to cytosolic DNA.
Journal ArticleDOI
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Paul A. Meyers,Glenn Heller,John H. Healey,Andrew G. Huvos,Joseph M. Lane,Ralph C. Marcove,A. Applewhite,Vaia Vlamis,Gerald Rosen +8 more
TL;DR: Intensive chemotherapy can achieve DFS for a high proportion of patients with osteogenic sarcoma and histologic response to preoperative chemotherapy cannot be assessed at diagnosis, although it is a powerful predictor of DFS.
Journal ArticleDOI
Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,Eugenie S. Kleinerman,Donna L. Betcher,Mark L. Bernstein,Ernest U. Conrad,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,John H. Healey,Andrew G. Huvos,Michael P. Link,Joseph Montebello,Helen Nadel,Michael Nieder,Judith K. Sato,Gene P. Siegal,Michael Weiner,Robert J. Wells,Lester E. Wold,Richard B. Womer,Holcombe E. Grier +23 more
TL;DR: The addition of MTP to chemotherapy might improve EFS, but additional clinical and laboratory investigation will be necessary to explain the interaction between ifosfamide and MTP.
Journal ArticleDOI
Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group
Paul A. Meyers,Cindy L. Schwartz,Mark Krailo,John H. Healey,Mark L. Bernstein,Donna L. Betcher,William S. Ferguson,Mark C. Gebhardt,Allen M. Goorin,Michael E. Harris,Eugenie S. Kleinerman,Michael P. Link,Helen Nadel,Michael Nieder,Gene P. Siegal,Michael A. Weiner,Robert J. Wells,Richard B. Womer,Holcombe E. Grier +18 more
TL;DR: The addition of ifosfamide to cisplatin, doxorubicin, and methotrexate did not enhance EFS or overall survival for patients with osteosarcoma, and the addition of MTP to chemotherapy resulted in a statistically significant improvement in overall survival and a trend toward better EFS.